Significant Benefits of Cadonilimab in Advanced Gastric Cancer
HONG KONG – Akeso recently announced noteworthy findings from their COMPASSION-15 study, a Phase III clinical trial that evaluated the effects of cadonilimab in patients suffering from advanced gastric cancers. This analysis was presented at a prominent medical oncology congress, showcasing the positive long-term survival outcomes of patients receiving this treatment.
Cadonilimab's Role in Treatment
Cadonilimab, Akeso's innovative PD-1/CTLA-4 bispecific antibody, has been rigorously evaluated in combination with established chemotherapy drugs, oxaliplatin and capecitabine, aimed at treating unresectable, locally advanced, recurrent, or metastatic gastric adenocarcinoma. During the presentation, Professor Shen Lin from a leading cancer hospital emphasized the consistent efficacy observed across various patient groups, particularly highlighting the treatment's impact on long-term survival rates.
Efficacy in Prognosis
With a median follow-up of approximately 33.9 months in this latest analysis, results indicated an impressive 39% reduction in the risk of death among patients who received cadonilimab compared to those who received standard care. Such a significant improvement in overall survival rate reaffirms confidence in the treatment's long-term benefits.
Focus on PD-L1 Expression Subgroups
Focusing on specific PD-L1 expression demographics, patients exhibiting CPS (combined positive score) ?5 experienced a remarkable 51% reduction in mortality risk. Conversely, those with CPS <5 showed a 24% decrease, illustrating that even patients with lower expression could derive meaningful benefits from cadonilimab treatment.
Consistency and Safety
Safety remains a priority, and results from the extended follow-up indicate that the cadonilimab combination therapy maintained a favorable safety profile, with no new safety concerns arising. This reaffirms its promise as a reliable treatment option for complex cancer cases.
Regulatory Approval and Clinical Guidelines
In September 2024, cadonilimab received official approval from the National Medical Products Administration (NMPA) for use in first-line treatment of advanced gastric cancer. This pivotal approval has paved the way for it to be listed in the 2025 CSCO Gastric Cancer Guidelines, earning a top recommendation based on its robust efficacy and safety data.
Innovative Development Pipeline
As a part of a leading biopharmaceutical company, Akeso is on a mission to revolutionize cancer treatment. This dedication is evident in their comprehensive research framework and innovative drug development strategies. Their growing portfolio of over 50 novel therapeutic candidates demonstrates their commitment to harnessing cutting-edge science in combatting various diseases, particularly in oncology.
Future Implications
The results shed light on a new era for gastric cancer treatment with promising possibilities. As Akeso continues to innovate, cadonilimab's role could change the landscape of treatment, providing new hope and options for patients facing daunting cancer journeys.
Frequently Asked Questions
What is cadonilimab?
Cadonilimab is a bispecific antibody targeting PD-1 and CTLA-4, developed by Akeso for cancer therapy.
What were the main findings from the COMPASSION-15 study?
The study demonstrated significant improvements in overall survival with cadonilimab compared to standard treatment, particularly in various PD-L1 expression subgroups.
How does cadonilimab compare to other treatments?
Cadonilimab has shown superior results in terms of survival benefits and is included as the only Category I recommendation for immunotherapy in gastric cancer treatment guidelines.
What is the importance of PD-L1 expression in this context?
PD-L1 expression levels help determine which patients may benefit most from cadonilimab, indicating its tailored therapeutic approach.
What future developments can we expect from Akeso?
Akeso is actively expanding its development pipeline, focusing on innovative cancer treatments and improving patient outcomes through advanced research.
